Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician’s Choice of Treatment in Spain

Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician’s Choice of Treatment in Spain

Abstract Introduction Elranatamab is a bispecific anti-B-cell maturation antigen (BCMA) and -CD3 antibody recently approved in Spain for the treatment of adult patients with triple-class exposed relapsed and refractory multiple myeloma (TCE-RRMM). The objective of this analysis was to assess its cos...

Full description

Saved in:
Bibliographic Details
Main Authors: Cristina Encinas, Virginia Lozano, Patrick Hlavacek, Julia Llinares, Sofía Toribio-Castelló, David Carcedo, Jordi Asís-Montalt, Joaquín Martínez-López
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-04-01
Series:Oncology and Therapy
Subjects:
Cost-effectiveness
Elranatamab
Multiple myeloma
Online Access:https://doi.org/10.1007/s40487-025-00333-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40487-025-00333-7

Similar Items